Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaC. Shen, G.Q. Yang, Nabil F. Saba et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 1
Safety of NBTXR3 Radioenhancer Delivery in Liver MetastasesB.D. Facer, É. Chajon, Changyu Shen et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0